Neonatal oxytocin manipulations have long-lasting, sexually dimorphic effects on vasopressin receptors.
Developmental exposure to oxytocin (OT) or oxytocin antagonists (OTAs) has been shown to cause long-lasting and often sexually dimorphic effects on social behaviors in prairie voles (Microtus ochrogaster). Because regulation of social behavior in monogamous mammals involves central receptors for OT, arginine vasopressin (AVP), and dopamine, we examined the hypothesis that the long-lasting, developmental effects of exposure to neonatal OT or OTA might reflect changes in the expression of receptors for these peptides. On postnatal day 1, prairie voles were injected intraperitoneally with either OT (1 mg/kg), an OTA (0.1 mg/kg), saline vehicle, or were handled only. At approximately 60 days of age, vasopressin V1a receptors, OT receptors (OTR) and dopamine D2 receptor binding were quantified using receptor autoradiography in brain tissue taken from males and females. Significant treatment effects on V1a binding were found in the bed nucleus of the stria terminalis (BNST), cingulate cortex (CgCtx), mediodorsal thalamus (MdThal), medial preoptic area of the hypothalamus (MPOA), and lateral septum (LS). The CgCtx, MPOA, ventral pallidum, and LS also showed significant sex by treatment interactions on V1a binding. No significant treatment or sex differences were observed for D2 receptor binding. No significant treatment difference was observed for OTR receptor binding, and only a marginal sex difference. Changes in the neuropeptide receptor expression, especially the V1a receptor, may help to explain sexually dimorphic changes in behavior that follow comparable neonatal manipulations.
Bales
K L
KL
Department of Psychology, University of California, Davis, CA 95616, USA. klbales@ucdavis.edu
Plotsky
P M
PM
Young
L J
LJ
Lim
M M
MM
Grotte
N
N
Ferrer
E
E
Carter
C S
CS
D000818:Animals; D000831:Animals, Newborn; D003411:Arvicolinae / Q000502:physiology*; D001345:Autoradiography; D005260:Female; D005917:Globus Pallidus / Q000378:metabolism; D008297:Male; D020645:Mediodorsal Thalamic Nucleus / Q000378:metabolism; D017072:Neostriatum / Q000378:metabolism; D009714:Nucleus Accumbens / Q000378:metabolism; D009951:Ornipressin / Q000031:analogs & derivatives / Q000494:pharmacology; D010121:Oxytocin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011301:Preoptic Area / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D017483:Receptors, Vasopressin / Q000187:drug effects*; D012686:Septal Nuclei / Q000378:metabolism; D020665:Septum of Brain / Q000378:metabolism; D012727:Sex Characteristics; D012919:Social Behavior
D017448:Receptors, Dopamine D2; D017483:Receptors, Vasopressin; C074541:vasotocin, desGly(NH2)(9)d(CH2)5-Tyr(Me)(2)-Thr(4)-Orn(8)-; D009951:Ornipressin; D010121:Oxytocin